Abstract:468 Objectives: Theranostic nanoparticles are expected to revolutionize future disease management. Despite promising preclinical theranostic outcomes, engineered nanomaterials still face major challenges for future clinical translation due to limitations such as high (>30 %ID/g) and long-term (>months) accumulation in the reticuloendothelial system (RES), lack of highly specific disease (such as tumor) targeting capability and lack of agents that can enable accurate tracking and therapy. Herein, we report novel ultrasmall mesoporous silica nanoparticles (USMSN) with enhanced in vivo accumulation in the tumor, as well as rapid clearance from the RES organs via the hepatobiliary route. USMSN were conjugated with the theranostic isotope pair 90/86Y for simultaneous PET imaging and radiotherapy in murine breast cancer models. Methods: USMSNs were synthesized using a facile one pot synthesis method, by carefully tuning the ratio of silica precursor and capping agent (polyethylene glycol-silane), followed by thorough characterization. USMSNs were further conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for radiolabeling with two isotopes of yttrium: 86Y (t1/2: 14.7 h) used for PET imaging and 90Y (t1/2: 64 h) for therapeutic purposes. 86Y-DOTA-USMSN were injected intravenously into 4T1 tumor bearing mice, followed by serial PET imaging and ex vivo biodistribution study to investigate their in vivo pharmacokinetics. For therapeutic studies, 4T1 tumor bearing mice (n=5 per group) were divided into 4 groups: 90Y-DOTA-USMSN (140 µCi), 90Y-DOTA (140 µCi), USMSN only and PBS only. Tumor growth and mouse body weight were monitored every other day. Cerenkov luminescence imaging (CLI) was also performed every other day on the mice injected with 90Y-DOTA-USMSN and 90Y-DOTA to monitor tumor uptake of the 90Y-labeled agents. Blood and histological analyses were performed at 0, 7, and 15 days post-injection, to evaluate treatment efficacy and safety. Results: Highly uniform, cubical mesoporous USMSN of ~ 9.89 ± 1.27 nm , with a high specific surface area of ~ 156.2 m2/g were successfully synthesized. 86Y-DOTA-USMSN showed prolonged blood circulation with significant signal from the blood pool at up to 24 h post-injection (p.i.) (from 29.4 ± 4.2 at 0.5h p.i to 10.2 ± 0.9 %ID/g at 24h p.i.). A rapid and prominent accumulation in the 4T1 tumor was observed which peaked at 24h p.i. (4.6 ± 0.8, 5.1 ± 0.4, 7.4 ± 1.1, 9.2 ± 1.6, 12.7 ± 0.9 and 10.4 ± 0.6 %ID/g at 0.5, 2, 6, 12, 24 and 48h p.i. respectively). 90Y-DOTA-USMSN treatment demonstrated significant reduction in tumor volume (relative tumor volumes of 0.78 ± 0.19, 0.74 ± 0.21, 0.77 ± 0.18, 0.85 ± 1.41, 0.85 ± 0.50 and 0.91 ± 0.24 at days 1, 3, 5, 7, 9 and 11 p.i) compared to 90Y-DOTA (relative tumor volumes from 1.19 ± 0.21 at day 1 p.i to 2.74 ± 0.42 at day 11 p.i). These results were further confirmed by CLI which demonstrated persistent but temporally shrinking uptake of 90Y-DOTA-USMSN in the 4T1 tumors. Conclusions: We have successfully demonstrated the first example of cancer theranostics in a preclinical model with 86/90Y-DOTA-USMSN. In vivo PET imaging demonstrated prolonged blood circulation and excellent tumor contrast with 86Y-DOTA-USMSN. CLI confirmed persistent retention of 90Y-DOTA-USMSN in the tumor and a significant inhibition of tumor growth, altogether indicating promising potential of USMSNs in future clinical cancer theranostics.

Cenosphere‐Based 177 Lu‐Aluminosilicate Microspheres as a Theranostic β ‐Emitter for Selective Internal Radiation Therapy of Hepatic Tumors

<SUP>177</SUP>Lu Radiolabelled AIE Dots for Multimodal Imaging Guided Photothermal/Radiopharmaceutical Tumor Therapy

Polymer composite microspheres loading 177Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer

Engineering Radioactive Microspheres for Intra‐Arterial Brachytherapy Using Radiation‐Induced Graft Polymerization

[90Y]Yttria Alumino Silicate Glass Microspheres: A Biosimilar Formulation to "TheraSphere" for Cost-Effective Treatment of Liver Cancer

Use of X-Ray Fluorescence Microscopy for Studies on Research Models of Hepatocellular Carcinoma

99mTc-radiolabeled composites enabling in vivo imaging of arterial dispersal and retention of microspheres in the vascular network of rabbit lungs, liver, and liver tumors

177Lu-Microspheres Selective Intra-arterial Radionuclide Therapy

Radioactive Lutetium Metallofullerene 177Luxlu(3-X)n@c80-pcbpeg Derivative: a Potential Tumor-Targeted Theranostic Agent.

Development of samarium-doped phosphate glass microspheres for internal radiotheranostic applications

131I-Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors Via Hepatic Artery Embolization

177 Lu Radiolabelled AIE Dots for Multimodal Imaging Guided Photothermal/Radiopharmaceutical Tumor Therapy

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy

Radioactive Polymeric Microspheres As a Novel Embolic Agent for Radiological Interventional Therapy: A Preliminary Evaluation

The Combined Therapeutic Effects of 131Iodine-Labeled Multifunctional Copper Sulfide-Loaded Microspheres in Treating Breast Cancer.

Y-86/90-Labeled Ultrasmall Mesoporous Silica Nanoparticles for Cancer Theranostics

Engineering Mesoporous Silica Nanoparticles for Targeted Alpha Therapy against Breast Cancer

pH-Responsive Upconversion Mesoporous Silica Nanospheres for Combined Multimodal Diagnostic Imaging and Targeted Photodynamic and Photothermal Cancer Therapy

(177)Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics.